Apyx Medical (APYX) Net Income towards Common Stockholders (2011 - 2026)

Apyx Medical (APYX) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$2.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 49.2% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (up 54.24% YoY) and the FY2025 annual result came in at -$11.2 million, up 52.22% from the prior year.
• Net Income towards Common Stockholders fell to -$2.1 million in Q1 2026, from -$1.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.0 million in Q2 2023 to a low of -$9.6 million in Q4 2023.
• A 5-year average of -$4.6 million and a median of -$4.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 81.3% — and 2024, when it plunged 543.38%.
• Tracing APYX's Net Income towards Common Stockholders over 5 years: stood at -$6.1 million in 2022, then plunged by 58.4% to -$9.6 million in 2023, then surged by 51.83% to -$4.6 million in 2024, then jumped by 71.93% to -$1.3 million in 2025, then sank by 62.28% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$1.3 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.